Mild cognitive impairment (MCI) refers to a neurocognitive disorder that is characterized by memory and thinking problems. The slight decline in mental abilities is more severe than normal aging but less severe compared to dementia. It is estimated that around 12 to 18% of individuals aged 60 years or above are living with mild cognitive impairment, with approximately 10 to 15% of patients developing dementia annually. Thus, the rising incidence of mild cognitive impairment, particularly among older adults, is expected to drive the drug pipeline expansion in the coming years.
The Mild Cognitive Impairment Drug Pipeline Report by Expert Market Research gives comprehensive insights into mild cognitive impairment drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for mild cognitive impairment. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The mild cognitive impairment pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from mild cognitive impairment.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing mild cognitive impairment pipeline development activities.
In mild cognitive impairment, people experience trouble with memory, language, and judgment. The cognitive decline does not affect the patient’s ability to perform everyday activities but is serious enough to be noticed by the affected individual or their family or friends. Mild cognitive impairment is classified into amnestic (affects primarily memory) and nonamnestic MCI (affects thinking abilities other than memory). Mild cognitive impairment can be an early stage of Alzheimer’s disease.
Currently, there is no standard mild cognitive impairment treatment or approved drugs. Robust efforts by pharmaceutical companies to develop novel therapies and innovations in diagnostic techniques such as neuroimaging and biomarker analysis are anticipated to advance medical care for this condition. Moreover, the rising interest of health regulatory bodies such as the U.S. Food and Drug Administration (FDA) in accelerating the approval of drugs for cognitive impairment and Alzheimer’s is likely to support pipeline expansion.
This section of the report covers the analysis of mild cognitive impairment drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
EMR’s mild cognitive impairment therapeutic assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration:
The mild cognitive impairment report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for mild cognitive impairment, with around 69 drugs undergoing phase II clinical development.
The drug molecule categories covered under the mild cognitive impairment pipeline analysis include small molecules, monoclonal antibodies, synthetic peptides, antibodies, cell therapies, gene therapies, recombinant proteins, and subunit vaccines. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for mild cognitive impairment.
The EMR mild cognitive impairment drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in mild cognitive impairment clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for mild cognitive impairment. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of mild cognitive impairment drug candidates.
The objective of the clinical trial is to evaluate the efficacy and safety of a blood pressure medication, spironolactone, for the treatment of mild cognitive impairment and early dementia in African American patients. The study is under Phase IV clinical development and has an estimated 30 participants.
This Phase II clinical study is aimed at evaluating the effects of the mild cognitive impairment drug candidate atorvastatin on brain vessel reactivity along with blood flow in people with mild cognitive impairment. The interventional study has enrolled about 20 subjects and is expected to be completed by December 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Mild Cognitive Impairment Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for mild cognitive impairment. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into mild cognitive impairment collaborations, regulatory environments, and potential growth opportunities within mild cognitive impairment pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share